Boehringer Ingelheim

Contract Development and Manufacturing Services for Biopharmaceuticals

Binger Strasse 173, 55216 Ingelheim am Rhein,Other, Germany



The Boehringer Ingelheim Group is one of the world’s 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 145 affiliates and more than 42,000 employees. Since it was founded in 1885, the family-owned company has been committed for 125 years to researching, developing, manufacturing and marketing novel products of high therapeutic value for human and veterinary medicine.

Contract development and manufacture of biopharmaceuticals

Today, Boehringer Ingelheim is one of the world’s leading companies for contract development and manufacture of biopharmaceuticals. All types of services from mammalian cell line or microbial strain development to final drug production can be delivered within a one-stop-shop concept. Boehringer Ingelheim delivers services for pre-clinical development up to global market supply with a strong commitment to its customers at its manufacturing facilities for mammalian cell culture and microbial fermentation.

Boehringer Ingelheim has brought 18 molecules to market and has many years of experience in multiple molecule classes such as monoclonal antibodies, recombinant proteins, interferons, enzymes, fusion molecules and plasmid DNA. Furthermore, high-titer platform technologies for new antibody mimetic formats such as scaffold proteins and antibody fragments are available for the manufacture of customer products.

Contract manufacturing of mammalian cell culture products and biopharmaceuticals

Boehringer Ingelheim offers the entire production technology chain at its biopharmaceutical manufacturing facilities in Vienna (Austria), Fremont (US) and Biberach (Germany). It has the world’s largest capacities for contract development and manufacturing of mammalian cell culture products and is one of the leading manufacturers of biopharmaceuticals.

Boehringer Ingelheim’s experience: process development (including proprietary high-expression systems in CHO, E.coli and yeasts) and manufacturing of biopharmaceuticals such as therapeutic proteins, monoclonal antibodies, antibody fragments, protein scaffolds, and plasmid DNA for clinical trials and global market supply.

Boehringer Ingelheim’s services in biopharmaceuticals manufacturing include:

Mammalian cell culture

Features of Boehringer Ingelheim’s mammalian cell culture services:

  • Clinical material capacities: 80l to 2,000l
  • Production capacities: 6 x 2,000l to 2 x 12,000l and 12 x 15,000l
  • Fed-batch operations

Microorganism fermentation

Boehringer Ingelheim’s microorganism fermentation services include:

  • Clinical material capacities: 30l to 6,000l
  • Production capacities: 1 x 300l to 2 x 6,000l
  • Batch or fed-batch fermentation

Downstream processing services

Boehringer Ingelheim’s biopharmaceuticals manufacturing services include downstream processing services:

  • Multi-product purification suites
  • Explosion-proof unit and preparative HPLC
  • Viral inactivation procedures

Pharmaceutical manufacturing services

Boehringer Ingelheim’s expertise extends to pharmaceutical manufacturing:

  • Up to 150,000 vials per batch aseptic filling
  • Up to 100,000 syringes per batch aseptic filling
  • Up to 150,000 cartridges per batch aseptic filling

Opportunities for Boehringer Ingelheim’s partners

Boehringer Ingelheim’s wide-ranging capabilities and expertise offer many advantages for its partners, including:

  • One-stop-shop from DNA to final dosage form
  • Project start without initial investment
  • Supply of biopharmaceuticals up to large quantities
  • Worldwide-licensed multi-product facilities on safety level 1

Samsung BioLogics’ Third Manufacturing Facility, Songdo

Samsung BioLogics opened its third biologics manufacturing plant in Songdo, South Korea, in October 2018. The plant made Samsung Group one of the world’s largest biologics contract manufacturing operators (CMO) in the world.

Boehringer Ingelheim Licenses ProBioGen’s Novel GlymaxX® Technology

Boehringer Ingelheim and ProBioGen have announced that they have signed a non-exclusive licensing agreement regarding ProBioGen's GlymaxX® technology. Boehringer Ingelheim's Contract Manufacturing Business will apply the technology to enhance ADCC (antibody-dependent cell-mediated cytotoxici

Boehringer Ingelheim Pharma GmbH & Co. KG

Binger Strasse 173

55216 Ingelheim am Rhein

Other

Germany

+49 6132 77 0 +49 6132 72 0 www.biopharma-cmo.com